TY - JOUR
T1 - Therapeutic agents for oxaliplatin-induced peripheral neuropathy; experimental and clinical evidence
AU - Kawashiri, Takehiro
AU - Mine, Keisuke
AU - Kobayashi, Daisuke
AU - Inoue, Mizuki
AU - Ushio, Soichiro
AU - Uchida, Mayako
AU - Egashira, Nobuaki
AU - Shimazoe, Takao
N1 - Funding Information:
This work was partly supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (JP20K07198).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research.
AB - Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research.
KW - Adverse effects
KW - Clinical evidence
KW - Oxaliplatin
KW - Peripheral neuropathy
KW - Preclinical data
UR - http://www.scopus.com/inward/record.url?scp=85100051369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100051369&partnerID=8YFLogxK
U2 - 10.3390/ijms22031393
DO - 10.3390/ijms22031393
M3 - Review article
C2 - 33573316
AN - SCOPUS:85100051369
SN - 1661-6596
VL - 22
SP - 1
EP - 25
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 3
M1 - 1393
ER -
